Oncogenic osteomalacia associated with phosphaturic mesenchymal tumour, mixed connective tissue type of the knee

Polish Journal of Pathology

Volumn 60, Issue 4, 2009, Pages 193-199

  Szumera Ciećkiewicz, Anna ^a   Ptaszyński, Konrad ^a   Pawełas, Andrzej ^a   Rutkowski, Piotr ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

FGF23; Fibroblast growth factor; Mesenchymal tumours; Oncogenic osteomalacia; Phosphaturia

Indexed keywords

ADULT; BONE TUMOR; CASE REPORT; DIFFERENTIAL DIAGNOSIS; HUMAN; KNEE; MALE; MESENCHYMOMA; OSTEOMALACIA; PATHOLOGY; REVIEW;

ADULT; BONE NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; KNEE JOINT; MALE; MESENCHYMOMA; OSTEOMALACIA;

EID: 77951644803     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Drezner MK. Tumor-induced osteomalacia. Rev Endocr Metab Disord 2001; 2: 175-186.
2. Kobayashi K, Imanishi Y, Koshiyama H, et al. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci. 2006; 78: 2295-2301.
3. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004; 28: 1-30.
4. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 1987; 59: 1442-1454.
5. Fukumoto S, Yamashita T. Fibroblast growth factor 23 is the phosphaturic factor in tumor induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens 2002; 11: 385-389.
6. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2002; 98: 6500-6505.
7. David V, Martin A, Hedge AM, et al. Matrix extracellular phosphoglycoprotein (MEPE) in a new bone renal hormone and vascularization modulator. Endocrinology 2009; 150: 4012-4023.
8. Toyosawa S, Tomita Y, Kishino M, et al. Expression of dentin matrix protein in tumours causing oncogenic osteomalacia. Mod Pathol 2004; 17: 573-578.
9. Habra MA, Jimenez C, Huang SC, et al. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract. 2008; 14:1108-1114.
10. Fukumoto S, Takeuchi Y, Nagano A, et al. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone 1999; 25: 375-377.
11. Dupond JL, Mahammedi H, Prie D, et al. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone 2005; 36: 375-378.
12. Hesse E, Moessinger E, Rosenthal H, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res. 2007; 22: 158-162.
13. Takeuchi Y, Suzuki H, Ogura S, et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004; 89: 3979-3982.
14. ADHR Consortium. Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26: 345-348.
15. Fukumoto S. Physiological regulation and disorders of phosphate metabolism - pivotal role of fibroblast growth factor 23. Int Med 2008; 47: 337-343.
16. Nabeshima Y. Discovery of α-Klotho unveiled new insights into calcium and phosphate homeostasis. Proc Jpn Acad 2009; 85:125-141.
17. Memon F, El-Abbadi M, Nakatani T. Does FGF23-klotho activity influence vascular and soft tissue calcification through regulating phosphate homeostatis? Kidney Int 2008; 74: 566-570.
18. Evans DJ, Azzopardi JG. Distinctive tumours of bone and soft tissue causing acquired vitamin-D-resistant osteomalacia. Lancet 1972; 1: 353-354.
19. Olefsky J, Kempson R, Jones H, et al. Tertiary hyperparathyroidism and apparent "cure" of vitamin-D-resistant rickets after removal of an ossifying mesenchymal tumor of the pharynx. N Eng J Med 1972; 286: 740-745.
20. Bahrami A, Weiss SW, Montgomery E, et al. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol 2009; 33: 1348-1354.
21. Williams K, Flanagan A, Folpe A, et al. Lymphatic vessels are present in phosphaturic mesenchymal tumours. Virchows Archiv 2007; 451: 871-875.